Could Hong Kong, mainland China benefit from more cross-border clinical trials?
Hong Kong patients could benefit from taking part in more clinical trials in mainland China, and vice versa for those on the other side of the border, according to the CEO of a government-owned institute that is exploring the projects and looking to boost biomedical innovation in the Greater Bay Area. Professor Bernard Cheung Man-yung,…